IS THERE UTILITY IN CLINICAL UTILITY MODELING FOR DIAGNOSTIC TECHNOLOGIES?

Author(s)

Hertz D, Taggart C, Waterman J, Armstrong S
GfK Custom Research, Wayland, MA, USA

OBJECTIVES: Demonstrating clinical utility is a challenge for diagnostic companies; MolDx denied 40% of CMS applications due to insufficient clinical utility data.  Trials to prove clinical utility can be expensive and lengthy. Modeling can be a relatively inexpensive method in establishing clinical utility for a novel diagnostic. The objective of this study was to determine the utility of and identify requirements and hurdles for developing clinical utility models.    METHODS: We conducted a qualitative review of 15 clinical utility models for novel diagnostics across diverse therapeutic areas and encompassing screening, diagnostic and monitoring tests.  Models were assessed based on data requirements, validity of outcomes, and ability to secure reimbursement. RESULTS: Clinical utility depends on: (1) test performance (relative to standard of care), (2) physician practice change (confidence in test results), (3) patient compliance/behavioral change, (4) availability and proven benefits of alternative treatment course, (5) and/or reductions in adverse events.   Modeling for clinical utility is most effective in areas where clear treatment protocols exist and evidence supporting the efficacy of an alternative treatment is robust. Evidence supporting practice change and patient compliance are frequently unknown, but may be informed by literature, claims analysis and/or EMR data.  Modeling clinical utility is most challenging when treatment guidelines are broad and outcomes evidence is not well differentiated.   CONCLUSIONS: Modeling is a logical first step in assessing clinical utility.  It's a cost-effective way of identifying a target population and best test placement in the continuum of care through comparison of alternative strategies.  Additionally, it can be useful in identifying evidence gaps and prioritizing data collection.  However unless the data supporting the model is strong, it is insufficient on its own to secure reimbursement.   Analysis of claims and EMR data can be an excellent data source for supporting diagnostic utility modeling.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PMD81

Topic

Health Policy & Regulatory

Topic Subcategory

Reimbursement & Access Policy

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×